CervoMed's Net Loss Nearly Doubles Amid Soaring R&D Costs

TL;DR

**CRVO is burning cash at an alarming rate, making it a risky bet despite ongoing trials.**

AI Summary

CervoMed Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $18,879,077, a 97% increase from the $9,584,781 loss in the same period of 2024. This was primarily driven by a substantial rise in operating expenses, with research and development (R&D) costs increasing by 36.5% to $15,986,865 from $11,711,746, and general and administrative (G&A) expenses rising by 16.4% to $7,974,277 from $6,850,536. Grant revenue also saw a considerable decline, falling 47.2% to $3,997,784 from $7,575,972. The company's cash and cash equivalents increased slightly to $9,437,400 as of September 30, 2025, from $8,999,496 at December 31, 2024, despite a decrease in total assets from $43,081,610 to $30,610,778. Strategic activities include the ongoing Phase 2a RESTORE Trial for ischemic stroke and the recently completed RewinD-LB Trial for dementia with Lewy bodies, with final results announced in October 2025. The company completed a private placement on April 1, 2024, raising approximately $149.4 million, and issued 550,000 shares of common stock, net of issuance costs, for $4,588,687 during the nine months ended September 30, 2025.

Why It Matters

CervoMed's escalating net loss and declining grant revenue signal increased financial pressure, which could impact its ability to fund critical clinical trials like the RESTORE Trial and future drug development. For investors, this raises concerns about dilution risk, especially given the recent private placement and common stock sales. Employees might face uncertainty if financial constraints lead to operational adjustments. In the competitive biopharmaceutical landscape, sustained losses could hinder CervoMed's ability to bring neflamapimod to market, potentially affecting patients awaiting treatments for conditions like DLB and ischemic stroke. The company's financial health is crucial for its long-term viability and competitive positioning.

Risk Assessment

Risk Level: high — CervoMed's net loss nearly doubled to $18,879,077 for the nine months ended September 30, 2025, from $9,584,781 in the prior year, indicating a significant increase in cash burn. Research and development expenses surged by 36.5% to $15,986,865, while grant revenue plummeted by 47.2% to $3,997,784, highlighting a widening gap between funding and expenditures. The company's total stockholders' equity decreased from $39,202,328 at December 31, 2024, to $26,011,464 at September 30, 2025, further evidencing financial deterioration.

Analyst Insight

Investors should exercise extreme caution and consider the high burn rate and declining grant revenue. Monitor upcoming announcements regarding the RESTORE Trial and the full results of the RewinD-LB Trial, as positive clinical data could provide a much-needed catalyst, but the current financial trajectory suggests significant risk.

Financial Highlights

debt To Equity

N/A

revenue

$3,997,784

operating Margin

-512.5%

total Assets

$30,610,778

total Debt

N/A

net Income

-$18,879,077

eps

-$2.10

gross Margin

N/A

cash Position

$9,437,400

revenue Growth

-47.2%

Revenue Breakdown

Key Numbers

• $18.88M — Net Loss (Increased 97% for the nine months ended September 30, 2025, compared to $9.58M in 2024.)
• $15.99M — Research and Development Expenses (Increased 36.5% for the nine months ended September 30, 2025, from $11.71M in 2024.)
• $3.99M — Grant Revenue (Decreased 47.2% for the nine months ended September 30, 2025, from $7.58M in 2024.)
• $9.44M — Cash and Cash Equivalents (As of September 30, 2025, a slight increase from $8.99M at December 31, 2024.)
• $26.01M — Total Stockholders' Equity (Decreased from $39.20M at December 31, 2024, to September 30, 2025.)
• 9,252,719 — Common Shares Outstanding (As of November 5, 2025, reflecting recent share issuances.)
• $149.4M — Gross Proceeds from 2024 Private Placement (Completed on April 1, 2024, providing capital for operations.)
• 550,000 — Shares of Common Stock Sold (Resulting in $4,588,687 net proceeds during the nine months ended September 30, 2025.)

Key Players & Entities

• CervoMed Inc. (company) — registrant
• Diffusion Pharmaceuticals Inc. (company) — former name of CervoMed Inc.
• EIP Pharma, Inc. (company) — accounting acquirer in the merger with Diffusion Pharmaceuticals Inc.
• SEC (regulator) — U.S. Securities and Exchange Commission
• NASDAQ Capital Market (market) — exchange where common stock is registered
• Leerink Partners LLC (company) — party to the Sales Agreement dated May 12, 2025
• NIA (regulator) — National Institute on Aging, awarded a $21.3 million grant
• Vertex Pharmaceuticals Incorporated (company) — party to the Option and License Agreement with EIP Pharma LLC
• Delaware (location) — state of incorporation
• Boston (location) — principal executive offices

FAQ

Risk Factors

• Increasing Net Loss and Burn Rate [high — financial]: The company reported a net loss of $18,879,077 for the nine months ended September 30, 2025, a 97% increase from the prior year's $9,584,781. This escalating loss, driven by higher R&D and G&A expenses, indicates a significant increase in cash burn, potentially impacting the company's ability to fund operations without additional capital.
• Dependence on Clinical Trial Success [high — operational]: CervoMed's progress is heavily reliant on the success of its clinical trials, such as the ongoing Phase 2a RESTORE Trial for ischemic stroke. Negative trial outcomes or delays could significantly impact future revenue streams and investor confidence.
• Declining Grant Revenue [medium — financial]: Grant revenue decreased by 47.2% to $3,997,784 for the nine months ended September 30, 2025, from $7,575,972 in the prior year. This substantial drop reduces a key source of non-dilutive funding and revenue, exacerbating the impact of rising operating expenses.
• Decreasing Total Assets [medium — financial]: Total assets have fallen from $43,081,610 at December 31, 2024, to $30,610,778 as of September 30, 2025. This decline is primarily due to a significant decrease in marketable securities ($17,856,688 from $29,922,523), suggesting asset liquidation or reduced investment, which could signal a need for cash.
• High Research and Development Expenses [medium — operational]: R&D expenses increased by 36.5% to $15,986,865 for the nine months ended September 30, 2025, from $11,711,746 in the prior year. While necessary for drug development, this substantial increase contributes significantly to the growing net loss and requires careful management.
• Dilution from Share Issuances [low — financial]: The company issued 550,000 shares of common stock, resulting in $4,588,687 in net proceeds during the nine months ended September 30, 2025. While providing capital, such issuances can dilute existing shareholders' ownership and earnings per share.

Industry Context

CervoMed operates in the biopharmaceutical sector, a highly competitive and capital-intensive industry focused on developing novel therapies. The sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on clinical trial outcomes, intellectual property protection, and the ability to secure substantial funding for research and commercialization.

Regulatory Implications

As a clinical-stage biopharmaceutical company, CervoMed is subject to stringent regulatory oversight by bodies like the FDA. Delays in clinical trials, adverse event reporting, or failure to meet regulatory standards for drug approval pose significant risks. Compliance with evolving regulations is critical for advancing its pipeline products.

What Investors Should Do

1. Monitor R&D Spend and Clinical Trial Progress
2. Assess Cash Burn Rate and Future Funding Needs
3. Evaluate Strategic Partnerships and Licensing Opportunities

Key Dates

• 2024-04-01: Completion of Private Placement — Raised approximately $149.4 million, providing crucial capital for operations and clinical development.
• 2025-09-30: End of Nine-Month Period — Reporting period for the 10-Q, showing a significant increase in net loss and changes in asset composition.
• 2025-10-01: Announcement of RewinD-LB Trial Results — Final results for the dementia with Lewy bodies trial were announced, providing data that could influence future strategic decisions and partnerships.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception that have not been offset by net income or additional paid-in capital. (Indicates the company has historically incurred more expenses than revenues, with a significant deficit of $89,610,561 as of September 30, 2025.)

Marketable Securities

Investments in financial instruments that are readily convertible to cash, such as stocks and bonds. (A significant decrease in marketable securities from $29,922,523 to $17,856,688 suggests the company may have sold these assets to fund operations.)

Grant Revenue

Revenue generated from grants, typically from government agencies or foundations, often for research purposes. (A substantial decline in grant revenue by 47.2% impacts the company's funding sources.)

Weighted Average Shares Outstanding

The average number of a company's outstanding shares over a specific period, used for calculating earnings per share. (Increased from 7,861,757 in the prior year to 8,970,668 for the nine months ended September 30, 2025, reflecting share issuances and impacting EPS calculations.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, CervoMed Inc. has experienced a substantial increase in its net loss, up 97% to $18.88 million. This is primarily driven by a 36.5% rise in R&D expenses and a 16.4% increase in G&A costs, while grant revenue has significantly declined by 47.2%. Total assets have decreased due to a reduction in marketable securities, although cash and cash equivalents saw a slight increase. The company's equity has also diminished, reflecting the ongoing operational losses.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CRVO NASDAQ Capital Marke
• $149.4 m — e gross proceeds of up to approximately $149.4 million, completed on April 1, 2024 401(
• $0 — mmon Stock the common stock, par value $0.001, of EIP issued and outstanding prio
• $21.3 million — al Institutes of Health NIA Grant the $21.3 million grant awarded to us by the NIA to suppo
• $21.0 million — the NIA to support the RewinD-LB Trial, $21.0 million of which was awarded in January 2023 an
• $0.3 million — arded in January 2023 and an additional $0.3 million of which was awarded in August 2024 NI
• $39.24 — of common stock at a purchase price of $39.24 per share issued in connection with the

Filing Documents

• crvo20250930_10q.htm (10-Q) — 1129KB
• ex_884815.htm (EX-10.1) — 55KB
• ex_885015.htm (EX-31.1) — 10KB
• ex_885016.htm (EX-31.2) — 10KB
• ex_885017.htm (EX-32.1) — 7KB
• ex_885018.htm (EX-32.2) — 7KB
• cervologo.jpg (GRAPHIC) — 25KB
• logosm.jpg (GRAPHIC) — 10KB
• 0001437749-25-033879.txt ( ) — 5502KB
• crvo-20250930.xsd (EX-101.SCH) — 45KB
• crvo-20250930_def.xml (EX-101.DEF) — 302KB
• crvo-20250930_lab.xml (EX-101.LAB) — 274KB
• crvo-20250930_pre.xml (EX-101.PRE) — 328KB
• crvo-20250930_cal.xml (EX-101.CAL) — 25KB
• crvo20250930_10q_htm.xml (XML) — 884KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1:

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 1 Item 2:

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 20 Item 3:

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 32 Item 4:

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 32 Part II

– OTHER INFORMATION

PART II – OTHER INFORMATION 34 Item 1:

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 34 Item 1A:

RISK FACTORS

ITEM 1A. RISK FACTORS 34 Item 2:

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 35 Item 3:

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 35 Item 4:

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 35 Item 5:

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 35 Item 6:

EXHIBITS

ITEM 6. EXHIBITS 35

Signatures

Signatures 36 i INTRODUCTORY NOTES Note Regarding Company References and Other Defined Terms As previously disclosed in our Current Report on Form 8-K filed on August 17, 2023 with the SEC, on August 16, 2023, the Delaware corporation formerly known as "Diffusion Pharmaceuticals Inc." completed a merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger, dated March 30, 2023 (the "Merger Agreement"), by and among Diffusion Pharmaceuticals Inc. ("Diffusion"), Dawn Merger Sub Inc., a wholly-owned subsidiary of Diffusion ("Merger Sub") and EIP Pharma, Inc. ("EIP"), pursuant to which Merger Sub merged with and into EIP, with EIP surviving the Merger a wholly-owned subsidiary of Diffusion (the "Merger"). Additionally, on August 16, 2023, Diffusion changed its name from "Diffusion Pharmaceuticals Inc." to "CervoMed Inc." For accounting purposes, the Merger is treated as a reverse recapitalization under U.S. GAAP and EIP is considered the accounting acquirer. Accordingly, EIP's historical results of operations are deemed the Company's historical results of operations for all periods prior to the Merger and, for all periods following the Merger, the results of operations of the combined company will be included in the Company's financial statements. Following the completion of the Merger, the business conducted by the Company became primarily the business conducted by EIP. Accordingly, unless the context otherwise requires, all references in this Quarterly Report to "CervoMed," the "Company," "we," "our," or "us," refer to the business of EIP for all dates and periods prior to August 16, 2023, and to the business of CervoMed for all dates and periods subsequent to (and including) August 16, 2023. We have also used several other defined terms in this Quarterly Report on Form 10-Q (the "Quarterly Report"), many of which are explained or defined below: Term Definition 2015 Equity Plan CervoMed Inc. 2015 Equity Incentive

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS CervoMed Inc. Condensed Consolidated Balance Sheets (unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 9,437,400 $ 8,999,496 Marketable securities 17,856,688 29,922,523 Prepaid expenses and other current assets 1,685,972 1,905,360 Deferred offering costs 269,331 — Grant receivable 1,361,387 2,254,231 Total current assets 30,610,778 43,081,610 Total assets $ 30,610,778 $ 43,081,610 Liabilities and Stockholders ' Equity Current liabilities: Accounts payable $ 1,349,219 $ 1,511,440 Accrued expenses and other current liabilities 3,250,095 2,367,842 Total liabilities 4,599,314 3,879,282 Commitments and Contingencies (Note 8) Stockholders' Equity: Series A preferred stock $ 0.001 par value: 30,000,000 authorized at September 30, 2025 and December 31, 2024, 0 shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value: 1,000,000,000 shares authorized at September 30, 2025 and December 31, 2024: 9,252,719 and 8,702,719 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 9,252 8,702 Additional paid-in capital 115,606,949 109,868,913 Accumulated other comprehensive income 5,824 56,197 Accumulated deficit ( 89,610,561 ) ( 70,731,484 ) Total stockholders' equity 26,011,464 39,202,328 Total liabilities and stockholders' equity $ 30,610,778 $ 43,081,610 See accompanying notes to unaudited condensed consolidated interim financial statements 1 CervoMed Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Grant revenue $ 322,569 $ 1,939,751 $ 3,997,784 $ 7,575,972 Operating expenses: Research and development 6,040,442 5,125,097 15,986,865 11,711,746

View Full Filing

View this 10-Q filing on SEC EDGAR